Skip to main content
. 2021 Jan 6;10(2):183. doi: 10.3390/jcm10020183

Figure 6.

Figure 6

Pravastatin affected mRNA expression of pro-angiogenic and anti-angiogenic molecules. Pravastatin (20 µM) significantly induced mRNA expression of pro-angiogenic molecules vascular endothelial growth factor A (VEGF-A) (A) and placental growth factor (PlGF) (B), whereas mevalonate alone had no effect. In immunoblot (C), treatment with pravastatin (200 µM) increased VEGF-A protein expression (D). Co-treatment with mevalonate (200 µM) reduced pravastatin induced VEGF-A and PlGF mRNA expression. mRNA expression of the anti-angiogenic molecule soluble fms-like tyrosine kinase-1 (sFlt-1) (E) and the angiogenesis-related protein endoglin (Eng) (F) was significantly reduced by pravastatin (200 µM). Mevalonate (200 µM) did not significantly affect sFlt-1 mRNA expression but, in combination with pravastatin, reversed the pravastatin effect on sFlt-1 mRNA expression in ECFCs. Results are from at least 3 independent runs. All runs were performed in triplicates. Con, control; Prava, pravastatin; Mev, mevalonate. * p < 0.05, ** p < 0.01; control group set as 1.